Epithelioma Treatment Market Size and Share
| Study Period | 2022 - 2030 |
| Market Size (2025) | USD 5.44 Billion |
| Market Size (2030) | USD 8.10 Billion |
| CAGR (2025 - 2030) | 8.58% |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | High |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Epithelioma Treatment Market Analysis by Mordor Intelligence
The Epithelioma Treatment Market size is estimated at USD 5.44 billion in 2025, and is expected to reach USD 8.10 billion by 2030, at a CAGR of 8.58% during the forecast period (2025-2030).
The increasing awareness of skin cancer prevention and the importance of early detection, supported by public health initiatives and advancements in diagnostic methods, is significantly contributing to the growth of the market. According to Skin Cancer Facts & Statistics data updated in January 2025, approximately 3.6 million cases of basal and squamous cell skin cancers are diagnosed each year in U.S., emphasizing the significant healthcare burden these conditions impose.
Furthermore, the treatment of epithelioma is increasingly shifting toward the adoption of combination therapies, which integrate immunotherapy with either targeted therapy or radiation. These approaches aim to enhance treatment efficacy while addressing the limitations of single-agent therapies. One notable example of a new product launch in combination therapies for epithelioma is Merck's KEYTRUDA. In September 2024, the FDA approved KEYTRUDA (an anti-PD-1 treatment) in combination with pemetrexed and platinum chemotherapy as a first-line treatment for adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM). This combination has shown significant improvement in overall survival compared to chemotherapy alone. By improving overall treatment outcomes and reducing the risk of resistance development, combination therapies are driving market growth as healthcare practitioners seek advanced and effective solutions for managing complex cases.
In addition, the U.S. FDA, along with other regulatory agencies, is increasingly supporting the expedited approval of innovative skin cancer treatments. The growing utilization of breakthrough therapy designations and fast track approvals is streamlining the process, ensuring quicker access to advanced treatment options for patients. For instance, in March 2024, BeiGene, Ltd. has received the U.S. FDA approval for TEVIMBRA (tislelizumab-jsgr) as a monotherapy for adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC). This regulatory support is driving the accelerated development, approval, and commercialization of skin cancer therapies, addressing critical patient needs more effectively.
However, the high treatment costs and economic barriers, regulatory challenges and approval processesare expected to restrain market growth.
Global Epithelioma Treatment Market Trends and Insights
Basal Cell Carcinoma Segment is Expected to Be Dominated the Market Over the Forecast Period
Basal cell carcinoma (BCC), a subtype of BCE, remains the most common form of skin cancer globally. The rising incidence of skin cancer, driven by increased UV radiation exposure due to environmental changes and lifestyle factors, has intensified the focus on advancing BCC therapies. Innovations such as targeted therapies and immunotherapies have significantly improved treatment outcomes, offering enhanced efficacy and better patient management. According to a study published by the National Library of Medicine (NLM) in April 2023, BCC accounts for approximately 80%-85% of non-melanoma skin cancer cases, emphasizing its significant burden on public health.
Moreover, leading companies in the market actively pursue mergers and acquisitions to strengthen their competitive position. These strategic initiatives help businesses enhance operational efficiency, expand their product portfolios, and increase overall capabilities. For instance, according to the article published by Medical University of Vienna in January 2025, researchers from Medical University of Vienna and University Hospital Vienna have reported promising outcomes from their study on a novel therapy. The active agent, TVEC, demonstrated effectiveness by reducing the size of basal cell carcinoma tumors in all participants. This reduction not only improved the feasibility of surgical removal but also led to complete tumor regression in some cases. These significant findings, published in the prestigious journal Nature Cancer, highlight the potential of TVEC as a groundbreaking treatment for basal cell carcinoma.
Therefore, owing to advanced healthcare infrastructure, significant R&D investments, major market players, a strong focus on cancer research and personalized medicine, and leadership in proteomics research, the basal cell carcinoma segment is expected to maintain its dominance in the market in the upcoming years.
North America is Expected to Dominate the Epithelioma Treatment Market
North America is poised to lead the market, driven by a high incidence of skin cancers and a robust healthcare infrastructure. In 2024, approximately 200,340 new melanoma cases are expected to be diagnosed in the United States, according to the 2024 report published by American Academy of Dermatology. This includes 99,700 noninvasive (in situ) cases and 100,640 invasive cases. Additionally, the prevalence of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) remains significantly high. Factors such as extensive UV exposure and an aging population continue to drive the demand for advanced treatment options in the region.
Furthermore, strong demand for advanced therapies and a steady pipeline of new drug approvals are expected to drive the growth of the market during the forecast period. This growth reflects the significant prevalence of non-melanoma skin cancers in the region. The regulatory framework in the U.S., particularly the FDA's accelerated approval programs, plays a pivotal role in facilitating faster access to innovative therapies. For instance, in December 2024, Cosibelimab, a novel drug targeting advanced cutaneous squamous cell carcinoma (CSCC) in adults, has received the green light from the FDA. This marks the first instance of a PD-L1 blocker being sanctioned for adults grappling with CSCC that has metastasized or is deemed inoperable by surgery or radiation. Furthermore, the increasing adoption of personalized medicine and precision oncology is significantly contributing to market growth, as these approaches enable more targeted, efficient, and patient-specific treatment options.
Therefore, owing to a high incidence of skin cancers, robust healthcare infrastructure, strong demand for advanced therapies, a steady pipeline of new drug approvals, the FDA's accelerated approval programs, and the increasing adoption of personalized medicine and precision oncology, the growth of the studied market is anticipated in the North American region.
Competitive Landscape
The epithelioma treatment market is fragmented in nature due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies which hold significant market share and are well known include Bristol-Myers Squibb Company; Merck & Co., Inc.; Novartis AG; Amgen Inc.; Pfizer Inc.; Sanofi; Johnson & Johnson Services, Inc.; F. Hoffmann-La Roche Ltd among others.
Epithelioma Treatment Industry Leaders
-
Bristol-Myers Squibb Company
-
Merck & Co., Inc
-
Novartis AG
-
Amgen Inc.
-
Pfizer Inc.
-
Sanofi
- *Disclaimer: Major Players sorted in no particular order
Recent Industry Developments
- August 2024: DermBiont is developing SM-020, a topical kinase inhibitor for basal cell carcinoma (BCC). Preliminary results from their Phase 2a study were promising. The SM-020 has shown promising results in their Phase 2a study for basal cell carcinoma (BCC). The study involved treating patients with SM-020 1% gel twice daily for 28 days. The primary endpoint was the percent change from baseline in the greatest tumor diameter at week 6.The results indicated significant tumor reduction, with no severe adverse events reported. This suggests that SM-020 could be a highly effective and well-tolerated treatment option for BCC.
- July 2024: Multitude Therapeutics' MT-116, an antibody-drug conjugate (ADC) for basal cell carcinoma, entered Phase I studies in July 2024. This first-in-human study aims to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of MT-116 in patients with advanced solid tumors. Preliminary results have shown promising outcomes. As of February 2024, eight patients have been treated with escalating doses of MT-116. No dose-limiting toxicities were observed, and the maximum tolerated dose has not been reached1. The most common treatment-related adverse events were fatigue and nausea, with only one Grade 3 adverse event (leukopenia) reported1. Additionally, some patients showed significant tumor shrinkage, indicating potential efficacy.
Global Epithelioma Treatment Market Report Scope
Epithelioma Treatment involves a comprehensive range of modalities, including surgical procedures, radiation therapy, chemotherapy, targeted therapy, and immunotherapy. Advances in medical technology have driven the adoption of minimally invasive techniques, which offer faster recovery times and fewer side effects for patients.
The epithelioma treatment market is segmented into type, drug class, distribution channel, and geography. By type, the market is segmented into basal cell carcinoma, squamous cell carcinoma, and other types. By drug class, the market is segmented into hedgehog pathway inhibitors, immune checkpoint inhibitors, chemotherapeutic agents, and other drug classes. By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, e-commerce, and other distribution channels. By geography, the market is segmented into North America, Europe, Asia-Pacific, South America, Middle East and Africa. The report also offers the market size and forecasts for 17 countries across the region. For each segment, the market sizing and forecasts have been done on the basis of revenue (USD).
| Basal cell carcinoma |
| Squamous cell carcinoma |
| Other types |
| Hedgehog pathway inhibitors |
| Immune checkpoint inhibitors |
| Chemotherapeutic agents |
| Other drug classes |
| Hospital pharmacies |
| Retail pharmacies |
| E-commerce |
| Other distribution channels |
| North America | United States |
| Canada | |
| Mexico | |
| Europe | Germany |
| United Kingdom | |
| France | |
| Italy | |
| Spain | |
| Rest of Europe | |
| Asia-Pacific | China |
| Japan | |
| India | |
| Australia | |
| South Korea | |
| Rest of Asia-Pacific | |
| Middle East and Africa | GCC |
| South Africa | |
| Rest of Middle East and Africa | |
| South America | Brazil |
| Argentina | |
| Rest of South America |
| By Type | Basal cell carcinoma | |
| Squamous cell carcinoma | ||
| Other types | ||
| By Drug Class | Hedgehog pathway inhibitors | |
| Immune checkpoint inhibitors | ||
| Chemotherapeutic agents | ||
| Other drug classes | ||
| By Distribution Channel | Hospital pharmacies | |
| Retail pharmacies | ||
| E-commerce | ||
| Other distribution channels | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Europe | Germany | |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Asia-Pacific | China | |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Middle East and Africa | GCC | |
| South Africa | ||
| Rest of Middle East and Africa | ||
| South America | Brazil | |
| Argentina | ||
| Rest of South America | ||
Key Questions Answered in the Report
How big is the Epithelioma Treatment Market?
The Epithelioma Treatment Market size is expected to reach USD 5.44 billion in 2025 and grow at a CAGR of 8.58% to reach USD 8.10 billion by 2030.
What is the current Epithelioma Treatment Market size?
In 2025, the Epithelioma Treatment Market size is expected to reach USD 5.44 billion.
Who are the key players in Epithelioma Treatment Market?
Bristol-Myers Squibb Company, Merck & Co., Inc, Novartis AG, Amgen Inc., Pfizer Inc. and Sanofi are the major companies operating in the Epithelioma Treatment Market.
Which is the fastest growing region in Epithelioma Treatment Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Epithelioma Treatment Market?
In 2025, the North America accounts for the largest market share in Epithelioma Treatment Market.
What years does this Epithelioma Treatment Market cover, and what was the market size in 2024?
In 2024, the Epithelioma Treatment Market size was estimated at USD 4.97 billion. The report covers the Epithelioma Treatment Market historical market size for years: 2022, 2023 and 2024. The report also forecasts the Epithelioma Treatment Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Page last updated on:
Epithelioma Treatment Market Report
Statistics for the 2025 Epithelioma Treatment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Epithelioma Treatment analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
